COMMENTARY

Single-Agent Topotecan Still Best for Recurrent or Platinum-Resistant Ovarian Cancer

Maurie Markman, MD

Disclosures

July 28, 2008


This feature requires the newest version of Flash. .
This feature requires the newest version of Flash. You can download it here.

Discuss Single-Agent Topotecan Still Best for Recurrent or Platinum-Resistant Ovarian Cancer


Source: Sehouli J, Stengel D, Oskay-Oezcelik G, et al. Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol. 2008;26(19):3176-82..

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....